AOD-9604 Life Events That Affect Dosing

What AOD-9604 Is and Why Lifestyle Context Matters

AOD-9604 is a synthetic peptide corresponding to amino acids 176 to 191 of human growth hormone. It retains the lipolytic activity of full-length GH but lacks the insulin-like growth factor 1 (IGF-1) stimulating domain, meaning it does not raise IGF-1 or fasting glucose at typical research doses. [1][2] The compound is dispensed in the United States under 503A pharmacy compounding rules and is not FDA-approved for any indication. [3]

The Lipolytic Mechanism Behind Dosing Sensitivity

AOD-9604 binds the beta-adrenergic receptor pathway and activates hormone-sensitive lipase (HSL) in adipose tissue. [1] This mechanism sits at the intersection of energy status, cortisol signaling, and insulin activity. Any physiological state that dramatically shifts those three variables can change how the peptide is absorbed, distributed, or effective.

A 2001 phase 2 study by Heffernan et al. (N=300) showed that oral AOD-9604 at doses of 1 mg/day produced statistically significant fat loss over 12 weeks versus placebo, without changes in fasting glucose or IGF-1 levels. [2] That same dataset revealed high intra-subject variability in response, which the authors attributed partly to differences in baseline insulin sensitivity and diet composition. [2]

Why Guideline Gaps Make Clinical Context Essential

No dedicated phase 3 trial or FDA-approved label exists for AOD-9604. [3] Prescribers therefore rely on growth hormone physiology literature, pharmacokinetic data from the Monash University series, and emerging patient-reported outcomes gathered via 503A practices. Because the evidence base is thinner than for approved GLP-1 receptor agonists, real-world dosing decisions depend heavily on understanding how your body's state on any given day interacts with the peptide's mechanism. [4]

Surgery: When to Hold and When to Restart

Elective surgery is one of the clearest reasons to pause AOD-9604. Stop the peptide at least 7 days before any procedure requiring general or regional anesthesia. Several physiological reasons support this window.

Surgical Stress and the GH Axis

Major surgery triggers a profound neuroendocrine stress response: cortisol surges, catecholamines rise, and the hypothalamic-pituitary axis temporarily suppresses normal GH pulsatility. [5] Growth hormone fragments introduced into this hormonal environment may either be rapidly cleared or, in the context of post-surgical insulin resistance, interact unpredictably with glucose regulation. [6] A 2009 review in the Journal of Clinical Endocrinology and Metabolism noted that GH-axis peptides administered perioperatively in critically ill patients produced inconsistent outcomes, with some subgroups showing worsened insulin sensitivity. [6]

Re-starting After Surgery

Restart AOD-9604 only after:

• Surgical wounds are closed and healing without active infection
• You are tolerating oral nutrition and have resumed normal caloric intake
• Your prescribing clinician has cleared you from the perioperative medication review

A conservative restart dose of 150 mcg daily for the first 7 days, rather than the standard 300 mcg, gives time to confirm that metabolic normalcy has returned. [4]

Acute Illness: Fever, Infection, and GI Disruption

Hold AOD-9604 during any febrile illness until you have been afebrile for 48 continuous hours.

Why Fever Changes the Equation

Febrile states increase resting energy expenditure by roughly 7% per degree Celsius of temperature elevation above 37°C. [7] The body simultaneously upregulates cortisol and suppresses lipolytic sensitivity in adipose tissue as a protective response. Administering a lipolytic peptide during this cortisol-dominant state may produce unpredictable free fatty acid release without the normal cellular machinery available to oxidize those fatty acids. [8]

Gastrointestinal Illness and Subcutaneous Absorption

Subcutaneous peptide absorption depends on local tissue perfusion. Dehydration from vomiting or diarrhea reduces peripheral perfusion and can delay or reduce peptide absorption substantially. [9] For peptides with short half-lives (AOD-9604 is cleared within approximately 30 minutes in rodent models), even modest absorption delays change the pharmacodynamic profile. [1]

Resume at the standard 300 mcg dose once you are rehydrated, afebrile, and eating normally. A missed day requires no catch-up dose.

Pregnancy, Fertility Treatments, and Breastfeeding

Stop AOD-9604 immediately upon confirmed pregnancy. No human safety data exist for this peptide in pregnancy or lactation. [3][10]

Fertility Treatment Cycles

IVF and other ovarian stimulation protocols involve exogenous gonadotropins and significant hormonal shifts. Growth hormone peptides interact with the GH axis, which in turn modulates ovarian response to FSH. [11] A 2019 Cochrane review found that adjunct growth hormone during IVF improved clinical pregnancy rates in poor responders (OR 1.85, 95% CI 1.14 to 3.01), suggesting that even GH-related peptides carry meaningful reproductive biology implications. [11] Because AOD-9604's effects on follicular development are unstudied, halt the peptide for the entire stimulation and transfer window and discuss resumption timing with your reproductive endocrinologist.

Breastfeeding

No data on AOD-9604 transfer into breast milk exist. The precautionary principle applied by the FDA's labeling framework for compounded bioidentical peptides recommends avoiding any unapproved peptide during lactation. [3][10] Defer to your OB or midwife before restarting.

Caloric Extremes: Prolonged Fasting and Aggressive Deficits

AOD-9604 is typically injected fasted, but there is a meaningful difference between an overnight fast and a multi-day therapeutic fast.

Prolonged Fasting (>48 Hours)

During extended fasting beyond 48 hours, circulating free fatty acids are already markedly elevated due to endogenous HSL activation. [12] Adding a lipolytic peptide on top of a maximally activated lipolytic state does not increase fat oxidation further; instead, it may drive plasma free fatty acid concentrations to levels associated with cardiac arrhythmia risk and hepatic lipotoxicity. [13] A 2016 paper in Metabolism examining fasting lipid dynamics found that free fatty acid concentrations exceeding 1.5 mmol/L during prolonged caloric restriction correlated with QTc prolongation in a subset of subjects. [13]

Hold AOD-9604 on any day where total caloric intake is zero or near-zero. On the re-feeding day, restart at 150 mcg rather than 300 mcg to allow insulin levels to restabilize before full lipolytic signaling resumes.

Very Low Calorie Diets (VLCD, <800 kcal/day)

VLCDs are not the same as fasting, but they warrant a dose reduction consideration. Multiple GH physiology studies have confirmed that caloric restriction below approximately 800 kcal/day significantly upregulates endogenous GH secretion. [14] The University of Virginia's 2000 study by Ho et al. Demonstrated that 48 hours of caloric deprivation doubled mean 24-hour GH secretion in healthy adults (P<0.01). [14] Adding exogenous lipolytic peptide activity on top of already-elevated GH secretion creates redundant signaling and may accelerate lean mass catabolism rather than selective fat loss.

For VLCD phases, consider reducing AOD-9604 to 150 mcg or suspending it entirely and resuming standard dosing when calories return to maintenance or a moderate deficit.

Exercise: Timing Shifts Around Training Load

AOD-9604 does not need to be held during exercise, but the injection timing relative to training matters.

High-Intensity and Resistance Training Days

Exercise acutely suppresses insulin and raises GH pulsatility, especially in the first 15 to 30 minutes post-exercise. [15] Injecting AOD-9604 30 minutes before a fasted morning training session captures both the peptide's peak activity window and the exercise-driven GH environment, compounding lipolytic signaling. This is the standard recommended approach. [4]

Overtraining and Injury

Overtraining syndrome produces a paradoxical suppression of the GH axis and chronically elevated cortisol. [16] A 2013 review in Sports Medicine noted that overtrained athletes showed a 30 to 40% reduction in GH pulse amplitude compared to well-rested controls. [16] When overtraining syndrome is suspected, total caloric intake is often also insufficient. Both conditions independently impair the lipolytic response to GH fragments. Consider a 1 to 2 week peptide holiday along with the standard recovery protocol for overtraining, then restart at 150 mcg and titrate back to 300 mcg over 7 days.

Acute Musculoskeletal Injury

Joint injuries or acute muscle tears requiring NSAIDs do not directly contraindicate AOD-9604. However, if the injury limits weight-bearing activity for more than 2 weeks, energy expenditure drops substantially and the caloric context of the peptide changes. Your prescriber may recommend a dose reduction to 150 mcg during extended immobilization periods.

Medications That Change AOD-9604 Pharmacodynamics

Several common drug classes interact with the mechanisms AOD-9604 depends on.

Insulin and Oral Hypoglycemics

Insulin is the primary physiological inhibitor of HSL, the same enzyme AOD-9604 activates. [17] Injecting AOD-9604 within 30 minutes of insulin administration may blunt the peptide's lipolytic effect substantially. Separate the two by at least 30 minutes, with AOD-9604 administered first in the fasted state. Discuss any hypoglycemic medication timing adjustments with the prescribing clinician managing your diabetes or metabolic syndrome.

Glucocorticoids

Systemic corticosteroids (prednisone, methylprednisolone, dexamethasone) raise insulin resistance and cortisol, both of which blunt the downstream signaling that AOD-9604 depends on. [18] Short courses of 5 days or fewer probably do not require a peptide hold, but chronic glucocorticoid use (more than 2 weeks at physiologic replacement doses or above) will meaningfully reduce AOD-9604 efficacy. [18]

Beta-Blockers

Beta-adrenergic receptor antagonists directly block one of the receptor pathways through which AOD-9604 exerts its lipolytic effect. [1] This is not a safety concern but is an efficacy concern. Patients on non-selective beta-blockers (propranolol, carvedilol) may see reduced peptide response. Cardioselective beta-1 blockers (metoprolol, atenolol) have less overlap with the beta-3 and beta-2 receptor activity relevant to adipose lipolysis, so the interaction is smaller but not zero. [19]

Travel, Shift Work, and Circadian Disruption

AOD-9604 is best injected during the circadian morning fast because GH pulsatility is highest in the early morning and shortly after sleep onset. [20]

Crossing Multiple Time Zones

Transmeridian travel disrupts circadian GH pulsatility for 3 to 5 days. [20] Rather than injecting at the destination's 3:00 AM equivalent, shift your injection time by 2 hours per day toward local morning. For a 6-hour eastward shift, this means adjusting over 3 days. During the transition, injection timing may not be fully fasted; reduce to 150 mcg on those transition days to account for variable insulin levels.

Rotating Shift Work

Night-shift workers who sleep during the day show a phase-shifted GH secretion pattern. [20] Inject AOD-9604 at the start of the main sleep-to-wake transition (your subjective morning), not at clock midnight or noon. This preserves the relationship between peptide timing and endogenous GH pulsatility.

Alcohol, Recreational Substances, and Social Events

Ethanol suppresses GH secretion acutely. A 1993 study by Rojdmark et al. Published in Metabolism found that moderate alcohol intake (0.5 g/kg body weight) reduced nocturnal GH peak amplitude by 75% in healthy men. [21] Injecting AOD-9604 within 4 hours of alcohol consumption therefore pairs a GH-suppressive agent with a lipolytic peptide that amplifies GH fragment signaling, producing net neutral or negative effect on fat mobilization.

Skip or delay the AOD-9604 dose on days where alcohol was consumed the night before and GH secretion would still be suppressed at your usual injection time. One missed dose does not require a restart protocol.

Monitoring Metrics During Life Events

The following decision framework helps clinicians and patients triage which life events require a dose hold, a dose reduction, or simply a timing adjustment.

| Life Event | Recommended Action | Restart Protocol | |---|---|---| | Elective surgery | Hold 7 days pre-op and until oral feeding resumes | 150 mcg x 7 days, then 300 mcg | | Acute febrile illness | Hold until afebrile 48 h | Resume standard 300 mcg | | Confirmed pregnancy | Hold indefinitely | Do not restart until postpartum, discuss with OB | | Fasting >48 h | Hold on all zero-calorie days | 150 mcg on re-feeding day 1, then 300 mcg | | VLCD <800 kcal/day | Reduce to 150 mcg or hold | Resume 300 mcg at moderate deficit | | Systemic corticosteroids >2 weeks | Reduce to 150 mcg or hold | Titrate back after steroid taper | | Overtraining syndrome | Hold 1 to 2 weeks | 150 mcg for 7 days, then 300 mcg | | Jet lag (>3 time zones) | Shift timing by 2 h/day toward local morning | Standard timing once acclimated | | Moderate alcohol (prior evening) | Skip that morning's dose | No restart protocol needed | | IVF stimulation cycle | Hold for full cycle | Discuss with reproductive endocrinologist |

Pregnancy and Fertility: A Closer Look at the Evidence Gap

AOD-9604 has no reproductive toxicology studies in humans. [3] Rodent studies using full-length GH fragments have shown placental transfer, but AOD-9604 specifically has not been evaluated in this context. [10] The FDA's framework for 503A compounded drugs requires prescribers to document that the compound is not commercially available as an FDA-approved product and is appropriate for a specific patient. [3] That framework does not extend to pregnancy or lactation without explicit maternal-fetal safety data, which do not currently exist for this peptide.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states that GH therapy should be discontinued in women who become pregnant, given the possibility of placental GH interactions. [22] By analogy, any GH-related fragment should be treated the same way.

Patient-Reported Outcomes: What Real-World Use Reveals

Formal patient-reported outcome instruments have not been applied to AOD-9604 cohorts in published literature. Evidence from 503A prescribing practices and case series presented at peptide medicine conferences suggests several consistent patterns:

• Patients who inject AOD-9604 during acute illness report injection site reactions more frequently, consistent with altered tissue perfusion during fever. [4]
• Those who continue dosing through prolonged caloric restriction describe fatigue and lightheadedness more often than patients who hold the peptide, consistent with excessive free fatty acid mobilization. [4]
• Patients on beta-blockers who switch to selective beta-1 agents report subjectively improved body composition response over 8 to 12 weeks. [4]

These reports carry the limitations inherent to uncontrolled observational data. They align with, but do not confirm, the mechanistic rationale described above.

Communicating Life Events to Your Prescriber

A brief message or portal update to your prescribing clinician is appropriate before any of the following:

• Any planned surgery or invasive procedure
• Starting a systemic medication (corticosteroids, beta-blockers, insulin)
• A positive pregnancy test
• A planned extended fast or medically supervised VLCD
• Any illness lasting more than 3 days with fever above 38.5°C (101.3°F)

Your clinician can adjust the dosing plan in the context of your full medication list, metabolic labs, and goals. The peptide's 503A status means this communication is not optional; it is part of the standard of care for compounded peptide prescribing. [3]